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Abstract
Background: The HIV-1 proviral genome harbors multiple CpG islands (CpGIs), both in the promoter and intragenic
regions. DNA methylation in the promoter region has been shown to be heavily involved in HIV-1 latency regulation in
cultured cells. However, its exact role in proviral transcriptional regulation in infected individuals is poorly understood
or characterized. Moreover, methylation at intragenic CpGIs has never been studied in depth.
Results: A large, well-characterized HIV-1 patient cohort (n = 72), consisting of 17 long-term non-progressors and 8
recent seroconverters (SRCV) without combination antiretroviral therapy (cART), 15 early cART-treated, and 32 late
cART-treated patients, was analyzed using a next-generation bisulfite sequencing DNA methylation method. In general,
we observed low level of promoter methylation and higher levels of intragenic methylation. Additionally, SRCV showed
increased promoter methylation and decreased intragenic methylation compared with the other patient groups. This
data indicates that increased intragenic methylation could be involved in proviral transcriptional regulation.
Conclusions: Contrasting in vitro studies, our results indicate that intragenic hypermethylation of HIV-1 proviral DNA is
an underestimated factor in viral control in HIV-1-infected individuals, showing the importance of analyzing
the complete proviral genome in future DNA methylation studies.
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Background
Current combination antiretroviral therapy (cART) can
successfully control human immunodeficiency virus type
1 (HIV-1) infection and prevent disease progression to
the acquired immunodeficiency syndrome (AIDS). How-
ever, a cure is not generally achievable due to the estab-
lishment of a latent reservoir of proviral HIV-1 DNA
which remains dormant and fuels viral rebound upon
treatment interruption [1–4]. Therefore, better insight
into the mechanisms regulating HIV-1 latency is crucial
in order to interfere with this latency state and to de-
velop cure strategies. The state of HIV-1 latency can be
defined as the transcriptional silencing of proviral genes
caused by multiple transcriptional blocks after the stable
integration of proviral DNA into the host genome [5].
Some of the major silencing mechanisms consist of epi-
genetic modifications, which have led to several clinical
trials investigating the latent viral reservoir reactivation
with histone deacetylase inhibitors, albeit with limited
success [6–10]. Other epigenetic modifications such as
HIV-1 proviral DNA methylation have also been de-
scribed in HIV-1 transcriptional silencing and have been
explored as targets for HIV-1 latency reversing strategy
[11–14].
DNA methylation is a well-described epigenetic modi-
fication in which a methyl group is added at the number
five carbon of the cytosine pyrimidine ring in CpG
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dinucleotides [15, 16]. This modification plays a role in
genome transcription regulation and is crucial in pro-
cesses such as the development of multicellular organ-
isms, cell differentiation, regulation of gene expression,
X-chromosome inactivation, genomic imprinting, and in
the suppression of parasitic and other repeat sequences
[15–23]. In general, reliable and stable transcriptional si-
lencing is caused if CpG islands (CpGIs)—stretches of
DNA that contain an increased frequency of CpG dinu-
cleotides (CG content > 50% and observed/expected
CpG ratio > 60%)—in promoter regions are hypermethy-
lated [12, 15, 16, 24, 25]. Methylation of CpGIs within
gene bodies (intragenic methylation) has been shown to
be involved in regulation of intragenic promoters, alter-
native splicing, and cellular differentiation, but also in
the activation of retroviruses, repetitive elements, and
prevention of aberrant transcript production [26–30].
The HIV-1 genome encodes five CpGIs [12]: two are
surrounding the promoter region and flanking the HIV-
1 transcription start site and several transcription factor
binding sites (e.g., TCF-1α, NF-κB, SP1) at the 5′ long
terminal repeat (LTR) region (CpGI LTR in the U3 re-
gion of the 5′ LTR and CpGI non-coding region (NCR),
downstream the HIV-1 5′ LTR (Fig. 1)) [12]. Two other
CpGIs are located in the env gene (CpGI ENV (35% con-
served) and CpGI env-tat-rev (ETR)), surrounding the
HIV-1 antisense open reading frame (Fig. 1) [12, 31].
The fifth CpGI is located in the 3′ LTR, where the anti-
sense transcription start site is located [12, 31]. In cul-
tured HIV-1-infected cells, the regulatory role of
proviral promoter methylation in viral transcriptional ac-
tivity is clearly demonstrated: hypermethylation stabi-
lizes HIV-1 latency and demethylating agents can induce
activation of HIV-1 transcription [12, 13, 32–34]. How-
ever, studies performed on DNA methylation in infected
individuals could not reproduce these findings indicating
that this in vitro regulation does not apply in vivo [14,
32, 35–38].
To further understand the role of proviral HIV-1 DNA
methylation in infected individuals, an NGS-based bisulfite
assay was developed to characterize HIV-1 proviral DNA
methylation profiles of both promotor and intragenic re-
gions in the context of a large, well-characterized patient
cohort (n = 72). This cohort comprises four different patient
groups as described by Malatinkova et al. [39]: 15 early
cART-treated individuals (ET), 32 late cART-treated indi-
viduals (LT), 17 long-term non-progressors (LTNP), and 8
acute seroconverters (SRCV).
Methods
Patient cohorts and DNA samples
HIV-1-positive patients were recruited from two clinical
centers, the Ian Charleson Day Centre (Royal Free Hos-
pital, London, UK) and the AIDS Reference Center (Ghent
University Hospital, Ghent, Belgium) during the study
performed by Malatinkova et al. [39]. Seventy-two HIV-1-
positive PBMC samples from that study were selected. Pa-
tients were divided into four cohorts based on their dis-
ease status (Additional Figure 1). The detailed study
design and inclusion criteria have been described previ-
ously [39]. Briefly, (1) long-term cART-treated individuals
(median treatment time of 10.77 years (interquartile range
(IQR), 6.46–12.34 years)) who had initiated treatment dur-
ing HIV-1 seroconversion (early treated (ET); n = 15) or
(2) during the chronic phase of the infection (late treated
(LT); n = 32); (3) cART-naïve long-term non-progressors
(LTNPs, n = 17) who had maintained HIV-1 viral load
(VL) ≤ 1000 copies/ml and CD4+ T cells > 500 cells/mm3
over > 7 years post-infection or (4) cART-naïve serocon-
verters (SRCV, n = 8), who were sampled during the acute
phase of the infection. Baseline characteristics and clinical
parameters of these cohorts are summarized in Table 1.
The Ethical Committees of Ghent University Hospital and
the Royal Free Hospital had approved this study (reference
numbers: B670201317826 (Ghent) and 13/LO/0729
(London)) with all study subjects giving their written in-
formed consent.
DNA from aliquots of 107 PBMCs was isolated using the
DNeasy® Blood & Tissue Kit (Qiagen, The Netherlands,
69504). Sample DNA concentration was determined with
Fig. 1 Location of the 5 CpGIs in the HIV-1 genome. The locations of the 5 CpGIs as described by Chavéz et al. [12] are indicated by red bars.
CpGI long terminal repeat (LTR) and non-coding region (NCR) are located around the HIV-1 promoter location. CpGI ENV and env-tat-rev are
located in the env gene. The fifth CpGI (3′ LTR) is located in the 3′ LTR region, where the antisense promoter region is found
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the Qubit dsDNA BR (broad range) Assay Kit (Thermo
Fisher Scientific, MA, USA, Q32850) on a Qubit 2.0
fluorometer according to the manufacturer’s instructions.
Cell culture
Jurkat cells (human T cell leukemia line) and J-Lat 8.4
(Jurkat cells infected with one HIV-1 copy per cell [44])
were cultured in a humidified atmosphere of 37 °C and
5% CO2 in RPMI 1640 medium with GlutaMAX™ Supple-
ment (Thermo Fisher Scientific, MA, USA, 61870-010),
supplemented with 10% FCS and 100 μg/ml penicillin/
streptomycin. The culture medium was renewed every 2
to 3 days. DNA was isolated as described in the previous
section.
Primer design
Primers targeting the 4 major HIV-1 CpGIs were de-
signed using 2 online available primer design tools
(Methprimer [45] and bisulfite primer seeker (Zymo
Research, CA, USA, https://www.zymoresearch.com/
pages/bisulfite-primer-seeker)). LTR primers were ob-
tained from Trejbalova et al. [13] and ETR_1 primers
from Weber et al. [37]. To evaluate primers in silico, the
bio-informatics tool developed by Rutsaert et al. [46], es-
timating the complementarity of each primer combin-
ation to all full-length HIV-1 sequences in the Los
Alamos National Laboratory (LANL) database (www.hiv.
lanl.gov) [47], was adapted: the database was trans-
formed to the bisulfite-treated variant (C→T; CG→CG),
nested primer combination analysis was included, as well
as analysis of combinations of multiple PCR assays. First,
the in silico analysis was used to evaluate primer combi-
nations that were obtained from literature as well as in-
house designed. Primer combinations matching at least
50% of the LANL database and nested combinations
with an overlap of at least 2/3 of the matched sequences
were retained. Selected primers were in vitro tested
using DNA from J-Lat 8.4 [44], diluted in Jurkat DNA at
different concentrations to mimic patient samples (10,
000, 5000, 1000, 500, 250, 100 HIV-1 copies per 106
cells). Finally, an additional in silico analysis was used to
select 4 or less primer combinations per CpGI that tar-
geted at least 60% of the LANL database. These final pri-
mer sequences are listed in Additional File 1.
Bisulfite treatment
A minimum of 5 × 1 μg of DNA per patient was bisulfite
treated using the Epitect Bisulfite kit (Qiagen, The
Netherlands, 59110), which is the least fragmenting
commercial bisulfite kit available, according to a previ-
ous in-house comparison [18]. We used the standard
protocol as provided by the manufacturer. The five ali-
quots per patient were pooled, and immediately stored
at – 20 °C.
Bisulfite-specific PCR
All PCR reactions were performed in triplicate to reduce
the probability of preferential amplification of one specific
amplicon that would dominate the output. Nested PCR
reactions were performed using the FastStart™ Taq DNA
Polymerase, 5 U/μl (Roche Applied Science, Belgium,
12032953001). A volume containing theoretically at least
Table 1 Clinical characteristics and viral reservoir markers of the four patient cohorts
Cohort 1 = ET Cohort 2 = LTNP Cohort 3 = LT Cohort 4 = SRCV
# patients 15 17 32 8
Clinical characteristics
Age (years) 45 (43–54.5) 49 (38–51) 48 (45–53.25) 37 (27–44.75)
Total cART (years) 11.65 (10.39–11.97) 0 (0–0) 9.80 (6.09–14.73) 0 (0–0)
Total VL suppression (years) 11.18 (9.82–11.37) 9.72 (0–14.67) 6.53 (5–10.42) 0 (0–0)
log VL zenith (copies/ml) 5.74 (5.31–5.88) 2.24 (1.79–2.76) 4.93 (4.24–5.52) 6.15 (5.14–6.31)
CD4 nadir (cells/μl) 413.5 (274.5–539.75) 624 (562–693) 154.5 (51.25–266.25) 483.5 (393.75–520.25)
CD4 at collection (cells/μl) 961 (737–1129.5) 793 (685–1010) 624.5 (484–885.5) 534 (393.75–617.50)
CD4/CD8 1.12 (0.8–1.47) 0.91 (0.82–1.47) 0.74 (0.6–0.93) 0.62 (0.37–0.87)
Viral reservoir markers
Total HIV-1 DNA* (c/M PBMC) [40] 88.14 (46.19–124.02) 48.01 (20.16–56.50) 137.01 (56.08–219.20) 1290.48 (519.63–4428.60)
Integrated HIV-1 DNA* (c/M PBMC) [41, 42] 158.00 (122.70–388.55) 28.16 (0–158.41) 586.65 (315.12–918.15) 1802.68 (272.19–3966.55)
CA HIV-1 usRNA (c/M PBMC) [43] 0.79 (0.28–3.12) 0.44 (0.27–3.51) 6.12 (1.80–10.08) 15.47 (0.62–77.60)
2-LTR circles (c/M PBMC) [40] 1.48 (0–3.03) 0.77 (0.65–2.70) 1.32 (0.57–2.18) 15.35 (4.82–24.12)
Values are reported as median (interquartile range), SRCV seroconverters, LTNP long-term non-progressors, PBMCs peripheral blood mononuclear cells, CA cell-
associated, usRNA unspliced RNA, cART combination antiretroviral therapy, VL viral load
*Total and integrated HIV-1 DNA measurements are performed using different assays and the absolute copies are therefore not directly comparable. To measure
integrated HIV-1 DNA, an Alu-HIV-1 qPCR is used whereas digital PCR is used to determine the total number of HIV-1 DNA copies
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ten bisulfite-treated HIV-1 copies (based on the droplet
digital PCR measurements as in Malatinkova et al. [39])
was added to the PCR mix containing 10 × PCR buffer,
2.5 U polymerase, 400 nM forward and reverse primers,
and 3% DMSO in a final volume of 25 μl. Each CpGI was
amplified with one nested primer combination, and after a
failed PCR reaction, the subsequent primer combination
was used (Additional File 1). Amplicons were visualized
using 3% agarose gel electrophoresis. Depending on the
selected primer, we used an in-house optimized PCR
amplification protocol or one of the two previously pub-
lished protocols [13, 37], as described in Additional File 1.
Sequencing
Bisulfite-treated amplicons were pooled equimolarly and
libraries were prepared using the NEBNext UltraII DNA
Library Prep Kit for Illumina (NEB, MA, USA, #E7645L/
#E7103L). These libraries were sequenced on a MiSeq se-
quencing system (MiSeq® Reagent Kit v3 (600 cycle), MS-
102-3003, Illumina). Sequencing reads were trimmed
using Trimmomatic (version 0.38), quality controlled
using FastQC (version 0.11.8), and subsequently mapped
to an in-house developed HIV-1 consensus genome using
the Bismark package (version 0.10.1) [48], providing a
conversion efficiency estimation and methylation state of
all analyzed CpGs.
Statistical analysis
HIV-1-specific amplicons with coverage > 250 were nor-
malized and divided into tiles (blocks of the HIV-1 gen-
ome containing the region of interest (LTR or env)).
Differential methylation analysis per region was per-
formed using the MethylKit package (version 1.6.3) in R
(version 3.5.1) [49, 50], including correction for overdis-
persion. P value calculation was performed using the
Chi-square test and p value correction for multiple test-
ing was performed within each comparison using false
discovery rate (FDR) [51, 52].
Spearman rank correlation analysis was performed to
explore correlations between DNA methylation (LTR and
env) and patient characteristics (HIV-1 reservoir and im-
munological parameters, obtained from Malatinkova et al.
[39]). Therefore, methylation data of both regions of every
individual was summarized by calculating an M value over
all CpGs using the formula as described by Du et al. [53].
Using stepwise regression model selection, linear regres-
sion models were developed for LTR and env methylation
densities to determine which independent variables may
explain variable DNA methylation in both regions.
Visualization was performed using R (version 3.5.1)
with the following packages: PMCMR (version 4.3),
Hmisc (version 4.2-0), graphics (version 3.5.1), ggplot2
(version 3.1.0), and corrplot (version 0.84) [50].
Results
In silico, in vitro, and in vivo HIV-1 DNA methylation
assay development
Three hundred thirty-eight different nested primer com-
binations (assays) (13 LTR, 303 NCR, 1 ENV, and 21
ETR) were subjected to an in silico analysis using an
adapted version of the bioinformatics tool developed by
Rutsaert et al. [46] to estimate the complementarity to
the Los Alamos National Library database, resulting in
70 nested PCR assays (2 LTR, 46 NCR, 1 ENV, and 21
ETR, Fig. 2a). The performance of these assays was sub-
sequently tested by PCR amplification in undiluted and
diluted J-Lat 8.4 DNA (up to 100 infected cells/106
cells), resulting in 36 assays (2 LTR, 15 NCR, 1 ENV,
and 18 ETR) that were capable of generating PCR prod-
ucts at the lowest dilutions (Fig. 2a). After a final in
silico analysis, a set of 9 primer combinations (2 LTR, 3
NCR, 1 ENV, and 3 ETR; Fig. 2 and Additional File 1)
was selected.
These nine assays were used to determine the HIV-1
methylation profile of HIV-1-positive blood samples.
The percentage of patients for whom the primer combi-
nations generated PCR amplicons is listed in Table 2.
This data demonstrates a similar trend as expected
based on the in silico analysis, being that a certain per-
centage of HIV-1 sequences would not be detected in
patients for certain primer combinations due to HIV-1
sequence variation. The difference between expected
amplification percentage and the actual amplification
percentage was 7.85%, 1.57%, 10.58%, and 3.57% for
LTR, NCR, ENV, and ETR, respectively (Table 2).
SRCV shows increased LTR methylation and decreased
env methylation
In all four patient cohorts together, average methylation
of all CpGs within the LTR region was 2.94% (IQR,
0.19–5.5%). When comparing patient cohorts, we ob-
served significantly higher LTR methylation in SRCV as
compared with all the other cohorts (ET, LT, and LTNP)
(Δ = 6.48%; q = 0.00029, Δ = 4.15%; q = 0.015, and Δ =
5.94%; q = 0.0044, respectively) (Fig. 3a).
Higher CpG methylation was observed in the env re-
gion as compared with LTR, averaging 28.86% (IQR,
8.73–39.44%). All cohorts (ET, LT, and LTNP) showed a
significantly higher methylation density compared with
SRCV (Δ = 33.47%; q = 0.013, Δ = 35.32%; q = 0.00017,
and Δ = 35.26%; q = 0.028, respectively) (Fig. 3b).
Correlations between HIV-1 methylation status and
reservoir markers
During the explorative correlation analysis, negative cor-
relations were found between the DNA methylation
density in the LTR region and the duration of viral sup-
pression (ρ = − 0.34; p = 0.020) and CD4+ T cell count
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at time of collection (ρ = − 0.27; p = 0.043) (Fig. 4a). How-
ever, we observed a significantly positive association for
DNA methylation in the env region and the CD4 T cell
count (ρ = 0.40; p = 0.0045) and cART duration (ρ = 0.39;
p = 0.0055) (Fig. 4a). Moreover, env methylation decreased
with increasing VL levels (ρ = − 0.39; p = 0.0063) and
higher CD4+ T cell nadir (ρ = − 0.33; p = 0.020) (Fig. 4a).
Based on the linear regression models, the only variable
that was independently associated with DNA methylation
in the LTR was the duration of VL suppression. Three
Fig. 2 Primer selection procedure. a Workflow used for the development of our DNA methylation assay determining HIV-1 DNA methylation in
HIV-1-infected patient samples. b Location of the nine different assays on the HIV-1 genome. Red arrows depict first round PCR primer location,
green arrows show second round PCR primer location, red bars indicate the location of the four analyzed CpGIs based on Chavez et al. [12]
Table 2 Performance of the nine final assays compared with the predicted performance using in silico analysis of the primer
complementarity
LTR NCR ENV ETR
# primer combinations 2 3 1 3
% of patients expected to generate amplicons based on in silico analysis* 59.25 80.37 89.42 60.33
% of patients in which DNA was amplified 51.40 81.94 100 63.90
% of patients for which the DNA had sufficient quality to be mapped to HIV-1 48.61 75.00 41.67 63.90
*In silico analysis is based on the bioinformatics primer evaluation tool as described by Rutsaert et al. [46]
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variables were independently associated with the env
methylation: VL, CD4 nadir, and CD4 count at time of
sampling (Fig. 4b).
Discussion
The lack of consensus about the role of proviral DNA
methylation in HIV-1 transcriptional regulation illus-
trates the need for a reliable and widely applicable
methylation assessment method. In this study, we first
described an in silico procedure to accurately predict the
complementarity of PCR assays to the HIV LANL data-
base, and an in vitro validation protocol to test the sensi-
tivity of the designed assays. This procedure resulted in
nine functional DNA methylation assays, designed
against the four most common CpGIs of the HIV-1 pro-
virus, which were consequently used to characterize
HIV-1 DNA methylation in a large, well-characterized
patient cohort. The in silico analysis was predictive of
the number of patient samples leading to successfully
amplified PCR products (Table 2), indicating that this is
an effective approach to prioritize testing of primer sets
in the context of HIV-1 or other pathogens with a high
sequence variability. In addition, as shown in the study
of Cortés-Rubio et al. [14], by using an NGS-based ap-
proach, our method fulfills the need to analyze a large
number of proviruses for each patient when compared
with the established Sanger sequencing-based methods
[54].
Across our four patient cohorts, we have found that
the HIV-1 provirus had low amounts of DNA methyla-
tion in the promoter region (average 2.94%, IQR 0.19–
5.5%) but substantially higher levels of intragenic (env)
methylation (average 28.86%, IQR 8.73–39.44%). When
comparing the differential methylation between the co-
horts, only SRCV showed distinct methylation profiles,
with increased LTR, and decreased env methylation.
Similarly, if patients were divided based on their VL sta-
tus (detectable VL (VL > 40 HIV-1 copies/ml plasma),
comprising all SRCV and 6/17 LTNPs. vs. undetectable
VL (VL < 40 HIV-1 copies/ml plasma), comprising ET,
LT, and 11/17 LTNPs), individuals with a detectable VL
had higher DNA methylation density in the HIV-1 LTR
region and a lower density in the env region compared
with those with an undetectable VL. These observations
might indicate that specific methylation profiles may be
associated with in vivo HIV-1 transcriptional control
and latency maintenance.
Indeed, since the involvement of DNA methylation in
HIV-1 latency was first described in 1987 [55], it has
been confirmed in HIV-1-infected cultured cells and la-
tency models that promoter methylation density is asso-
ciated with silencing stability: DNA methylation
induction can initiate/stabilize HIV-1 latency, while
methylation inhibitors as 5-aza-2′-deoxycytidine (5-aza-
CdR) cause HIV-1 reactivation and display clear syner-
gistic effects with other latency reversing agents [11–13,
32–34, 36, 56–58]. These studies reported a major role
of promoter DNA methylation in latency regulation,
which was in line with the general concept of transcrip-
tion regulation by DNA methylation: hypermethylation
of the promoter region suppresses both basal promoter
activity and responses to activating stimuli, and hypome-
thylation is a transcription mark [57]. However, DNA
methylation studies on patient-derived samples have
shown—with the exception of some LTNPs—the same
trend as in our present observation: low level of DNA
methylation in the promoter region, even in patients
suppressing VL successfully, therefore not following the
predictions from the in vitro experiments [37, 38]. It has
been shown that DNA methylation behavior in cell lines
is often drastically different from that of in vivo cells due
to completely different epigenetic environments and
Fig. 3 HIV-1 proviral DNA methylation comparison between patient cohorts. a Summary of the methylation data in the LTR region (CpGI LTR +
CpGI NCR) using average methylation over all CpGs in the region. b Summary of the methylation data in the env region (CpGI ENV + CpGI ETR)
using average methylation over all CpGs in the region. q = FDR-corrected p values for multiple testing. LT late treated, ET early treated, SRCV
acute seroconverter, LTNP long-term non-progressor
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immortalization, sometimes producing unreliable re-
sults in terms of predicting in vivo DNA methylation
events [59, 60]. Some studies, however do show in-
creasing LTR DNA methylation over time [13], or dy-
namic profiles in patients when measured
longitudinally [14]. We could not confirm these data
since we only measured single time point samples of
patients with similar treatment time/time of viro-
logical control (except for the SRCV). The low abun-
dance of DNA methylation in the promoter region of
HIV-1 indicates that other (epigenetic) factors as inte-
gration site epigenetics or cell type might be more
important for transcriptional regulation than promoter
methylation.
Fig. 4 Spearman correlations between HIV-1 proviral DNA methylation and patient characteristics. a Correlation of DNA methylation with several
virological and viral reservoir markers in HIV-1-infected individuals. Positive and negative correlations are depicted in red and blue, respectively.
Non-significant correlations are left blank. Correlations with covariates that independently explained methylation in the linear regression models
are depicted with a black frame. b Correlation plots between DNA methylation (M value) and the independent variables from the linear models.
Upper left, LTR methylation vs. duration of VL suppression. Upper right, env methylation vs. log VL. Lower left, env methylation vs. CD4 nadir.
Lower right, env methylation vs. CD4 count
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In previous DNA methylation studies in HIV-1 pa-
tients, the focus was on promoter methylation assess-
ment [13, 14, 32, 36–38]. In contrast to promoter
methylation, the role of intragenic DNA methylation in
general transcriptional regulation is less clearly described
[26–30]. Studies outside of the HIV-1 field have sug-
gested that intragenic methylation could have a role in
the activation of retroviruses, repetitive elements, alter-
native splicing, transcription initiation in canonical pro-
moters of embryonic stem cells, and prevention of
aberrant transcript production [28–30]. Moreover, intra-
genic methylation has been shown to be a robust pre-
dictor of gene transcription in genes with a CpGI
containing promoter [61]. In our study, decreased env
methylation levels in individuals with active ongoing
replication (SRCVs) suggests that intragenic methylation
increases in the case of proviral transcriptional silencing,
leading to higher methylation in latently infected cells or
in those in which viral replication is blocked. Indeed,
cART-treated patients and LTNP have lower viral tran-
scription (measured as cell-associated unspliced RNA
(CA usRNA)) than SRCV (Table 1) and env methylation
shows an inverse correlation with CA usRNA within the
SRCV cohort (ρ = − 0.81; p = 0.014). Furthermore, intra-
genic methylation did correlate positively with the CD4+
T cell count, linking high intragenic methylation with
viral control. Intragenic methylation was also negatively
associated with the VL, a measure that indicates ongoing
replication.
In contrast to what was proposed by LaMere et al.
[54], we have found no statistical difference between
proviral methylation in LTNP with undetectable VL (la-
tent infection) and treated patients (cART-induced sup-
pression) (LTR: Δ = 0.85%, q = 0.74; env: Δ = 2.29%, q =
0.94). This could be due to the low number of LTNPs
with undetectable VL.
In general, the lack of promoter DNA methylation in
HIV-1 proviral genomes in vivo suggests that this modi-
fication is of subordinate importance in the regulation of
the viral life cycle compared with the more abundant,
yet less studied intragenic DNA methylation. Our obser-
vations indicate that intragenic DNA methylation could
be a late event during infection. Methylation of the pro-
viral genome may occur stochastically during years of
viral control, yet act as a stable epigenetic mark once
established. This may subsequently affect transcription,
including splicing, of viral transcripts, which could affect
viral replication by interaction with transcriptional
elongation (tat) or export of viral RNA (rev). Neverthe-
less, additional in vitro and in vivo experiments targeting
the (intragenic) DNA methylation are required to evalu-
ate the exact impact on the HIV-1 life cycle. Especially
temporal changes of intragenic methylation would be
very informative, yet our study was limited by the lack of
longitudinal sampling. Other limitations include the fact
that although the cohort size was much larger than pre-
vious studies [13, 14, 32, 36–38], the patient groups de-
scribed here were not balanced, not in size, nor for sex,
and age. Additionally, we did no specific CD4+ T cells
selection. The use of PBMCs could potentially mask dif-
ferential methylation since it is shown that LRAs have
cell-type specific effects, indicating cell-type specific epi-
genetic profiles [62]. Moreover, due to the targeted na-
ture of the methodology, it does not allow to provide
information about integration site methylation or repli-
cation competence of the analyzed provirus. Finally, we
did not provide information about the fifth CpGI (3′
LTR), nor did we analyze non-CpGI CpGs.
Conclusions
Altogether, our study illustrates the underestimation of
the role of intragenic proviral DNA methylation in pa-
tient samples. Previous studies have mainly focused on
LTR methylation and have interpreted LTR methylation
as a transcriptional regulatory factor, ignoring any po-
tential role of env methylation [13, 35, 38]. We suggest
that both env and LTR methylation are involved in HIV-
1 transcription regulation and that env methylation
could be an important predictor of viral transcription
in vivo. However, we also suggest that proviral promoter
methylation is hindered/inhibited in all HIV-1-positive
patients, especially those on cART, but that its density
still influences viral transcription rate.
The exact functions of DNA methylation of these two
regions should be clarified by performing additional ex-
periments using longitudinal follow-up studies to moni-
tor proviral DNA methylation dynamics within patients,
starting early during infection, and ideally continuing
over a period of multiple years of cART. Different CD4+
T cell types should be analyzed separately to avoid cell-
type dependent bias of the data. If HIV-1-positive pa-
tients were to undergo treatment interruption, DNA
methylation profiles should also be monitored in order
to understand the methylation dynamics during viral re-
bound. Moreover, proviral intragenic non-CpGI methy-
lation analysis could also provide a better understanding
of HIV-1 latency regulation by DNA methylation. Here,
we do provide a useful tool to help design and estimate
the sample size needed in these studies. Altogether,
these insights should be of paramount importance when
looking at the various strategies to control HIV-1 after
discontinuation of cART and for the HIV-1 cure field.
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